Fuji Pharma Co., Ltd. Reports Consolidated Earnings Results for the Three Months Ended December 31, 2019; Provides Consolidated Earnings Guidance for the Six Months Ending March 31, 2020 and Fiscal Year Ending September 30, 2020; Provides Dividend Guidance for the Second Quarter Ending March 31, 2020 and Fiscal Year Ending September 30, 2020
February 05, 2020
Share
Fuji Pharma Co., Ltd. reported consolidated earnings results for the three months ended December 31, 2019. For the three months, the company reported net sales of JPY 8,968 million compared to JPY 10,279 million a year ago. Operating profit was JPY 1,053 million compared to JPY 1,605 million a year ago. Profit was JPY 745 million compared to JPY 1,096 million a year ago. Earnings per share was JPY 23.92 compared to JPY 36.63 a year ago.
The company provided consolidated earnings guidance for the six months ending March 31, 2020 and full year ending September 30, 2020. For the six months ending March 31, 2020, the company expects consolidated net sales of JPY 16,647 million, operating profit of JPY 1,209 million and profit attributable to owners of the parent of JPY 781 million or JPY 25.09 per share.
For the full year ending September 30, 2020, the company expects consolidated net sales of JPY 33,830 million, operating profit of JPY 2,571 million and profit attributable to owners of the parent of JPY 1,664 million or JPY 53.44 per share.
The company provided dividend guidance for the second quarter ending March 31, 2020 and fiscal year ending September 30, 2020. The company expects to pay a dividend of JPY 14.00 per share for the second quarter ending March 31, 2020 compared with JPY 14.00 per share for the same period a year ago.
The company expects to pay a year-end dividend of JPY 15.00 per share for the fiscal year ending September 30, 2020 compared with JPY 15.00 per share for the fiscal year ended September 30, 2019.
Fuji Pharma Co., Ltd. is a Japan-based company mainly engaged in the manufacture and sale of medical products. The Company is engaged in the manufacture and sale of hormone medicines for obstetrics and gynecology department, as well as injectable drugs for radiological department such as radiopaque dye for urinary tracts and blood vessels through its branches. In addition, the Company purchases its main pharmaceutical ingredients from its main parent company.
Fuji Pharma Co., Ltd. Reports Consolidated Earnings Results for the Three Months Ended December 31, 2019; Provides Consolidated Earnings Guidance for the Six Months Ending March 31, 2020 and Fiscal Year Ending September 30, 2020; Provides Dividend Guidance for the Second Quarter Ending March 31, 2020 and Fiscal Year Ending September 30, 2020
FUJI PHARMA CO., LTD. 
